Trump announces "planned partnership" of U.S. Steel, Nippon Steel
"US Steel will REMAIN in America, and keep its Headquarters in the Great City of Pittsburgh," Trump said in a post on Truth Social.
"This will be a planned partnership between United States Steel and Nippon Steel, which will create at least 70,000 jobs, and add 14 Billion Dollars to the U.S. Economy. The bulk of that Investment will occur in the next 14 months," Trump said.
The president also noted that he will attend a big rally at the U.S. Steel headquarters in Pittsburgh on May 30.
Although the term "merger" was not explicitly used, Politico reported that Trump's remarks showed that he had approved a deal for Nippon Steel to buy U.S. Steel, "reversing a position he took during the presidential campaign."
The move also overturns former President Joe Biden's decision to halt the deal shortly before leaving office in January. Both Biden and Trump had previously expressed a desire for the iconic American company to stay under U.S. ownership.
In February, Trump said Nippon Steel will no longer seek to purchase U.S. Steel and will instead "invest heavily" in the U.S. company. The 14.1-billion-U.S. dollar acquisition of Pittsburgh-headquartered U.S. Steel that Nippon Steel has now dropped is a "concept psychologically not good," Trump said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
12 minutes ago
- New Straits Times
Trump slams allies' plan to recognise Palestinian state
WASHINGTON: President Donald Trump has expressed displeasure with leaders of France, the United Kingdom and Canada for saying they plan to recognise a Palestinian state in September, Press Secretary Karoline Leavitt said Thursday. Recent announcements by some of Washington's closest allies have only hardened the US president's stance against the move. While Trump slammed Canada for announcing its intention to recognise Palestinian statehood at a United Nations meeting in September, he has been milder in his criticism of French President Emmanuel Macron and British Prime Minister Keir Starmer. He dismissed Macron's decision, which got the ball rolling last week for other countries to consider similar steps, saying the statement did not "matter" and "doesn't carry much weight." Starmer this week said the UK will formally recognise a Palestinian state in September unless Israel takes "substantive" steps, including agreeing to a ceasefire in Gaza. Asked about Britain's decision after a trip to Scotland and talks with Starmer, Trump said he was "not in that camp, to be honest." According to Leavitt, Trump is now more critical of the push for recognition and believes it amounts to "rewarding Hamas at a time where Hamas is the true impediment to a cease fire and to the release of all of the hostages."--AFP
The Sun
42 minutes ago
- The Sun
Trump increases tariff on Canada to 35%, White House says
WASHINGTON: U.S. President Donald Trump signed an executive order on Thursday increasing tariffs on Canadian goods to 35% from 25%, the White House said. The new rates goes into effect on August 1. 'In response to Canada's continued inaction and retaliation, President Trump has found it necessary to increase the tariff on Canada from 25% to 35% to effectively address the existing emergency,' the White House said - REUTERS
The Sun
42 minutes ago
- The Sun
Trump pressures 17 pharma CEOs to cut US drug prices
WASHINGTON: President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly , Sanofi, Regeneron, Merck & Co , Johnson & Johnson, and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about 2% each, while the NYSE Arca Pharmaceutical Index fell 3% on Thursday. Trump called on drugmakers to provide so-called most-favored-nation prices to every patient enrolled in the government Medicaid health program for low-income people, and to guarantee such pricing for new drugs. The policy is aimed at cutting U.S. prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the U.S. to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favored-nation prices. Trump gave companies until September 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower U.S. prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the U.S.,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new U.S. manufacturing plants. U.S. patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis , AbbVie, and German Merck KGaA's U.S. division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said-REUTERS
